284 related articles for article (PubMed ID: 27689695)
41. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
[TBL] [Abstract][Full Text] [Related]
42. Targeting DNA methylation in cancer.
Szyf M
Bull Cancer; 2006 Sep; 93(9):961-72. PubMed ID: 16980240
[TBL] [Abstract][Full Text] [Related]
43. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
44. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
45. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
Khan H; Vale C; Bhagat T; Verma A
Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
[TBL] [Abstract][Full Text] [Related]
46. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic therapy--a new development in pharmacology.
Peedicayil J
Indian J Med Res; 2006 Jan; 123(1):17-24. PubMed ID: 16567863
[TBL] [Abstract][Full Text] [Related]
48. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
49. Hypoxia Alters Epigenetic and
Greville G; Llop E; Huang C; Creagh-Flynn J; Pfister S; O'Flaherty R; Madden SF; Peracaula R; Rudd PM; McCann A; Saldova R
Front Oncol; 2020; 10():1218. PubMed ID: 32850359
[No Abstract] [Full Text] [Related]
50. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
51. Epigenetic reprogramming in breast cancer: from new targets to new therapies.
Katz TA; Huang Y; Davidson NE; Jankowitz RC
Ann Med; 2014 Sep; 46(6):397-408. PubMed ID: 25058177
[TBL] [Abstract][Full Text] [Related]
52. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.
Kikuchi M; Yamashita K; Waraya M; Minatani N; Ushiku H; Kojo K; Ema A; Kosaka Y; Katoh H; Sengoku N; Enomoto T; Tanino H; Sawanobori M; Watanabe M
Oncotarget; 2016 Jan; 7(2):1741-53. PubMed ID: 26646320
[TBL] [Abstract][Full Text] [Related]
54. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
55. Epigenetics in ovarian cancer.
Natanzon Y; Goode EL; Cunningham JM
Semin Cancer Biol; 2018 Aug; 51():160-169. PubMed ID: 28782606
[TBL] [Abstract][Full Text] [Related]
56. Epigenomics and ovarian carcinoma.
Maldonado L; Hoque MO
Biomark Med; 2010 Aug; 4(4):543-70. PubMed ID: 20701443
[TBL] [Abstract][Full Text] [Related]
57. 5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer.
Saldova R; Dempsey E; Pérez-Garay M; Mariño K; Watson JA; Blanco-Fernández A; Struwe WB; Harvey DJ; Madden SF; Peracaula R; McCann A; Rudd PM
Epigenetics; 2011 Nov; 6(11):1362-72. PubMed ID: 22086115
[TBL] [Abstract][Full Text] [Related]
58. The role of epigenetic modifications in drug resistance and treatment of breast cancer.
Karami Fath M; Azargoonjahromi A; Kiani A; Jalalifar F; Osati P; Akbari Oryani M; Shakeri F; Nasirzadeh F; Khalesi B; Nabi-Afjadi M; Zalpoor H; Mard-Soltani M; Payandeh Z
Cell Mol Biol Lett; 2022 Jun; 27(1):52. PubMed ID: 35764927
[TBL] [Abstract][Full Text] [Related]
59. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.
Zhao L; Guo H; Chen X; Zhang W; He Q; Ding L; Yang B
Eur J Pharmacol; 2022 Jul; 927():175071. PubMed ID: 35636522
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
Matei DE; Nephew KP
Gynecol Oncol; 2010 Feb; 116(2):195-201. PubMed ID: 19854495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
